Clinical Trials In The News

These Clinical Trials have been featured in recent newspaper or magazine articles, or on the radio or TV:

• RI (RAGE Inhibitor) Study -- The Alzhiemer's Disease Cooperative Study and Pfizer are now recruiting participants for a trial of a new drug developed as an inhibitor of the Receptor for Advanced Glycation Endpoints (RAGE) protein. The study will recruit nearly 400 volunteers at 40 U.S. Research sites. Click here for more information on the trial.

• Bapineuzumab in Patients with Mild to Moderate AD -- Elan Pharmaceuticals is now recruiting participants for a trial of a humanized monoclonal antibody at 129 sites across the U.S.

• IGIV (Immune Globulin Intravenous) Study – The Alzheimer's Disease Cooperative Study will soon begin recruiting participants for a passive immunization trial of intravenous immunoglobulin (IGIv) for reducing brain amyloid. IGIv is a well-known treatment with an established safety record, approved for use for other indications for more than 25 years. Thirty-six to 40 sites are expected to participate through a partnership with Baxter Pharmaceuticals, recruiting 360 individuals between the ages of 55 to 90 with probable AD. Most sites will use home-health nurses to administer the IGIv bi-weekly for 72 weeks. Sign up for the IGIV Email Alert to receive updates on this study and the addition of new sites.

• Home-Based Assessment for Alzheimer Disease Prevention (HBA) is now recruiting participants.

• Alzheimer's Disease Genetics Study seeks families with 2 or more siblings with AD.

AD Genetics Study Brochure (PDF, 196K)

*E-mail Alerts* Subscribe to our AD Clinical Trials e-mail alert service.

E-mail us your questions about the Clinical Trials Database.

Back to Search